Proqr Therapeutics vs Pyxis Oncology
Proqr Therapeutics is the larger business, with $18.0m of revenue in fiscal 2025 against $13.9m for Pyxis Oncology (1.3 times as much). Proqr Therapeutics grew faster (-12.1% against -14.2%). Proqr Therapeutics kept more of each dollar of sales as profit: a net margin of -265.2% against -574.5%. Pyxis Oncology carries less debt relative to equity (0.0% against 9.9%).
| Latest fiscal year | Proqr TherapeuticsPRQR, 2025 | Pyxis OncologyPYXS, 2025 |
|---|---|---|
| Revenue | $18.0m | $13.9m |
| Revenue growth | -12.1% | -14.2% |
| Net income | −$47.7m | −$79.6m |
| Operating margin | -273.1% | -609.2% |
| Net margin | -265.2% | -574.5% |
| Return on equity | -63.8% | -91.4% |
| Free cash flow | −$60.8m | −$63.5m |
| Cash | $108m | $15.4m |
| Total debt | $5.7m | $0 |
| Debt to equity | 9.9% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 56 |
| Market value | $144m | $104m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 5 buys, 0 sales | 1 buys, 1 sales |